Compare MMI & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMI | SDGR |
|---|---|---|
| Founded | 1971 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2013 | 2020 |
| Metric | MMI | SDGR |
|---|---|---|
| Price | $27.01 | $18.68 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $29.00 | $25.33 |
| AVG Volume (30 Days) | 469.8K | ★ 860.1K |
| Earning Date | 02-13-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $751,284,000.00 | $256,951,000.00 |
| Revenue This Year | $11.94 | $23.69 |
| Revenue Next Year | $15.59 | $20.46 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 20.74 | ★ 32.90 |
| 52 Week Low | $26.87 | $15.99 |
| 52 Week High | $41.94 | $28.47 |
| Indicator | MMI | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 38.92 | 55.04 |
| Support Level | $26.87 | $17.50 |
| Resistance Level | $28.32 | $19.58 |
| Average True Range (ATR) | 0.64 | 0.68 |
| MACD | 0.03 | 0.10 |
| Stochastic Oscillator | 7.24 | 63.67 |
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.